2609.HK
Legend Biotech is a biotech

Cancer hospital operator Bayzed Health Group Inc. (2609.HK) launched its Hong Kong IPO on Friday, aiming to raise up to HK$900 million ($115 million). The company said it plans to sell 133 million shares at between HK$4.22 and HK$6.75 per share, according to its announcement marking the listing’s launch.

Final pricing will take place on June 19, with trading set to begin on June 23.

Bayzed operates six self-owned hospitals around China engaged in the detection and treatment of cancer. The company reported 1.19 billion yuan ($166 million) in revenue last year, up 11% from 1.07 billion yuan in 2023. Its loss for 2024 narrowed to 13.5 million yuan from a 24.6 million yuan loss the previous year.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Yalla is a gaming company

Yalla kicks off new chapter with new midcore games

The Middle Eastern social media and gaming company plans to launch its first two midcore games this quarter, with another self-developed ‘roguelike game’ to follow Key Takeaways: Yalla revealed it…
Fu Shou Yuan does funeral memorial services

Slowing economy haunts undertaker Fu Shou Yuan

China’s top funeral services provider fell into the red in the first half of this year, extending a year of revenue and profit declines in 2024 Key Takeaways: Fu Shou…
Wynn Macau bets on concerts

Wynn Macau bets on concerts as a winning strategy

After missing the mark with its quarterly earnings, the Macao casino operator is building a big entertainment complex as an added draw for tourists Key Takeaways: Disappointing gaming results from…